Adverse Effects of Androgen Deprivation in Elderly Men with Prostate Cancer
- 6 Downloads
Purpose of Review
The purpose of this review is to summarize the key literature of complications and adverse effects experienced by elderly men undergoing androgen deprivation therapy for prostate cancer, as well as evidence-based strategies to manage these complications.
Current research demonstrates several adverse effects associated with treatment with androgen deprivation therapy, including skeletal complications, possible cardiovascular effects, diabetes and metabolic complications, decreased sexual function and libido, depression, and cognitive decline.
Despite the well-known side effect profile of androgen deprivation therapy for prostate cancer, little evidence-based guidance for management of these complications exists outside of skeletal health. Prospective studies are needed to determine the effect of androgen deprivation therapy on cardiovascular disease in older adults, and prospective trials are needed to assess diagnostic and therapeutic interventions in this large, vulnerable patient population.
KeywordsAndrogen deprivation Hormonal treatment Prostate cancer Complications Geriatric
Compliance with Ethical Standards
Conflicts of Interest
Dr. Morgans reports personal fees from Janssen, Genentech, AstraZeneca, Astellas, Bayer, and Sanofi, outside the submitted work.
Dr. Shevach and Dr. Zarzour each declare no conflict of interest.
Human and Animal Rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.Google Scholar
- 9.•• Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines committee of the american college of p. treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39 This is an important paper from the American College of Physicians that summarizes the guidelines of osteoporosis prevention and treatment including men on hormonal treatment. PubMedCrossRefPubMedCentralGoogle Scholar
- 11.Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–7 discussion 7.PubMedCrossRefPubMedCentralGoogle Scholar
- 13.Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83(8):1561–6.PubMedCrossRefPubMedCentralGoogle Scholar
- 17.NCCN Clinical practice guidelines in oncology: Prostate cancer. Version 3.2018 2018.Google Scholar
- 37.Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495–502.PubMedCrossRefPubMedCentralGoogle Scholar
- 39.Kappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126(8):934–41.PubMedCrossRefPubMedCentralGoogle Scholar
- 41.• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–96 In this meta-analysis of 8 retrospective studies, ADT was associated with worse cardiovascular outcomes, particularly in men with history of cardiovascular disease. Although data from other studies were not conclusive, and patients need to be counseled on these potential serious complications. PubMedCrossRefPubMedCentralGoogle Scholar
- 47.•• Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41 This is a practical paper that establishes a multistep approach to prevent and manage cardiovascular complications of ADT. This approach should be followed by treating physicians to prevent detrimental effects of such complications. PubMedPubMedCentralCrossRefGoogle Scholar
- 48.•• Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–7 In this prospective study, patients treated with ADT had worsening cognitive function compared with age-matched controls. The risk of cognitive decline with ADT needs to be considered and patients need to be educated on such risk. PubMedPubMedCentralCrossRefGoogle Scholar
- 54.•• Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34(16):1905–12 This study showed possible correlation between ADT and depression which can cause significant morbidity in the elderly patients with prostate cancer. PubMedPubMedCentralCrossRefGoogle Scholar